Mary Cardosa

World Health Organization provides voluntary medical services. It is the United Nations' agency for health. WHO is governed by countries that approve funding, programs and policies related to public health and health related social issues through the world health assembly. Some of the health and social issues which the organization addresses are communicable & non-communicable diseases, community & family health, hunger, health technology, mental health, pharmaceuticals and sustainable development. Founded on April 7, 1948, the organization is headquartered in Geneva, Switzerland.

International Association for the Study of Pain operates as a professional forum for science, practice, and education in the field of pain. It brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain. The company was founded in 1973 and is headquartered in Washington, DC.

Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia.

Grand Challenges Canada provides support services for healthcare. It specializes in global health, innovation, global mental health, international development, impact investing, maternal, newborn and child health, and research and development. The company was founded in May 2010 is headquartered in Toronto, Canada.

PrimeraDx, Inc. develops and commercializes molecular diagnostics systems. It offers ICEPlex System, an open platform that allows clinical researchers to design their assays for the development of multiplexed, multimodal, and quantitative in vitro diagnostic to simultaneously interrogate dozens of biomarkers in the same reaction. The company's ICEPlex System also enables to design complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, miRNAs, and fusion genes, as well as addresses research challenges in oncology, infectious diseases, translational medicine research, and pharma quality control. It also focuses on developing oncology products that are intended to support cancer research, diagnostics, and therapeutics; and companion diagnostics solutions that help pharmaceutical companies to design, develop, and validate custom CDx tests. The company was founded by Vladimir I. Slepnev in 2004 and is headquartered in Mansfield, MA.